Selective Targeting of Tumor and Stromal Cells By a Nanocarrier System Displaying Lipidated Cathepsin B Inhibitor | Zendy

Mikhaylov G. | Zendy; Klimpel D. | Zendy; Schaschke N. | Zendy; Mikac U. | Zendy; Vizovisek M. | Zendy; Fonovic M. | Zendy; Turk V. | Zendy; Turk Boris | Zendy; Vasiljeva Olga | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Premium

Selective Targeting of Tumor and Stromal Cells By a Nanocarrier System Displaying Lipidated Cathepsin B Inhibitor

Author(s) -

Mikhaylov G.,

Klimpel D.,

Schaschke N.,

Mikac U.,

Vizovisek M.,

Fonovic M.,

Turk V.,

Turk Boris,

Vasiljeva Olga

Publication year - 2014

Publication title -

angewandte chemie international edition

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 5.831

H-Index - 550

eISSN - 1521-3773

pISSN - 1433-7851

DOI - 10.1002/anie.201402305

Subject(s) - cathepsin b , internalization , nanocarriers , ex vivo , stromal cell , cancer research , in vivo , cathepsin , chemistry , drug , pharmacology , biology , biochemistry , cell , enzyme , microbiology and biotechnology

Cathepsin B (CtsB) is a lysosomal cysteine proteinase that is specifically translocated to the extracellular milieu during cancer progression. The development of a lipidated CtsB inhibitor incorporated into the envelope of a liposomal nanocarrier (LNC‐NS‐629) is described. Ex vivo and in vivo studies confirmed selective targeting and internalization of LNC‐NS‐629 by tumor and stromal cells, thus validating CtsB targeting as a highly promising approach to cancer diagnosis and treatment.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research